search button

Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review)

  • Authors:
    • Ana Maria Vladareanu
    • Carsten Müller-Tidow
    • Horia Bumbea
    • Sinziana Radesi

  • View Affiliations

  • Published online on: March 1, 2010     https://doi.org/10.3892/or_00000674
  • Pages: 595-604
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The Philadelphia negative chronic myeloproliferative neoplasms are hematological disorders with several diagnostic challenges. Due to recent molecular findings, the WHO classification of Tumors of Hematopoietic and Lymphoid Tissue 2008 reorganized the field of chronic myeloproliferative diseases. Thus, specific molecular markers provide important information for current diagnostic strategies. This review highlights the important diagnostic tools in classical and atypical myeloproliferative neoplasms mainly the JAK2V617F mutation, the Mpl receptor, Polycythemia rubra vera 1 (PRV1), platelet-derived growth-factor receptor α (PDGFRA), platelet-derived growth-factor receptor β (PDGFRB), fibroblast growth-factor receptor 1 (FGFR1) and c-kit tyrosine kinase. A description of the origin, clinical correlations and role in diagnosis and therapy is provided for each of these molecular markers.

Related Articles

Journal Cover

March 2010
Volume 23 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.8
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.5
  • CiteScore Rank: Q1: #74/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.719
  • SCImago Journal Rank (SJR): 0.864
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Vladareanu AM, Müller-Tidow C, Bumbea H and Radesi S: Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review). Oncol Rep 23: 595-604, 2010.
APA
Vladareanu, A.M., Müller-Tidow, C., Bumbea, H., & Radesi, S. (2010). Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review). Oncology Reports, 23, 595-604. https://doi.org/10.3892/or_00000674
MLA
Vladareanu, A. M., Müller-Tidow, C., Bumbea, H., Radesi, S."Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review)". Oncology Reports 23.3 (2010): 595-604.
Chicago
Vladareanu, A. M., Müller-Tidow, C., Bumbea, H., Radesi, S."Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review)". Oncology Reports 23, no. 3 (2010): 595-604. https://doi.org/10.3892/or_00000674